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ANTISENSE C-MYC THERAPY 
Antisense technology evolved from the desire to specifically inhibit 
tumor cell growth without bringing about file systemic toxicity 
seen with conventional cytotoxic and biologic agents. Similarly, the 
goal of controlling neointimal hyperplasia requires the inhibition of 
a specific cell population. SMC proliferation is one of the major 
causes for failure of both percutaneous and traditional vascular 
interventions in the 2 month-to-3 year postoperative period. 
Control of this response in human trials remains elusive) The 
specificity and more central site of action afforded by antisense 
therapy could prove a useful adjunct in improving the long-term 
outcome of vascular interventions. 
The myc gene was first identified as the viral oncogene of avian 
myelocytomatosis.2 Subsequently, it was identified in the vertebrate 
genome as c-myc. 3 The gene sequence ishighly conserved across 
vertebrate species, and rearrangements have been found in numer- 
ous animal and human cancers. 4's The products of the myc gene are 
a pair of DNA-binding phosphoproteins localized to the nucleus 
that recognize a short segment of DNA upstream from its own 
gene. 6
The exact role these protein products play in cell proliferation 
is unknown. Their importance appears to be related to DNA 
synthesis. Inhibition of DNA, but not RNA, synthesis can be 
achieved with a monoclonal antibody to c-myc protein. This 
inhibition is similar to that obtained with antibodies to DNA 
polymerase alpha. 7During the G O phase, myc mRNA is absent 
from the nucleus; however, it is the earliest mRNA to accumulate 
when quiescent cells are stimulated to proliferate, s-i° Only low 
levels of the c-myc phosphoproteins appear to be needed to induce 
cell proliferation i nontransformed cells, and their half-life is very 
short) 1 Germane to this discussion are the specific effect ofc-myc 
phosphoproteins on vascular smooth muscle cells (VSMC). Mito- 
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gen stimulation of quiescent VSMCs causes an increase in c-myc 
protein with a peak at 2 to 4 hours, with low levels required 
throughout the cell cycle, n Similarly, down-regulation f c-myc 
transcription has been noted with the treatment ofknown antipro- 
liferative agents. 1~ The protooncogenes c-myc, c-fos, and c-myb 
represent the "final common pathway" for transmittal of the 
multiple different mitogenic signals at the cell membrane to the 
nuclear synthetic machinery. These properties make the c-myc gene 
an attractive target for directed gene therapy to modulate cellular 
proliferation. 
Initial AS experiments to c-myc used a 15 mer deoxytibonucle- 
otide to inhibit the c-myc protein increase after mitogen stimula- 
tion. Peripheral blood cells were also blocked at the Gi /s  interface, 
but able to traverse Go to G 1. Sequence specificity of this 15-mer 
OGD is suggested by heteroduplex formation in HL-60 promy- 
elocytlc ells. This set of experiments confirmed adecrease c-myc 
protein level by 50% to 80% and noted an induction of myeloid 
differentiation with c-myc suppression. 13,14 In vascular smooth 
muscle cells (VSMC) AS to c-myc exhibits adose-dependent ffect 
on suppression of cell proliferation in response to mitogenic 
stimulation from either a quiescent or proliferative state. Is c myc 
protein and mRNAlevels are also decreased by AS c-myc treatment 
as demonstrated byELISA, Western blot, and quantitative PCR 
techniques, i ,16 This effect has also been demonstrated in the rat 
carotid artery, porcine coronary artery injury model balloon injury 
and human smooth muscle cells and was associated with a decrease 
in neointimal hyperplasia. 16,17 
The mechanism by which the AS sequences produce their 
effect is unknown, but is thought to act through sequence-specific 
hybridization to transcriptional mRNA and inhibition of further 
transcription or increasing the susceptibility to ribonuclease H. 
Questions have arisen with respect to the sequence-spedfic effect of 
the c-myc and c-myb AS sequences used in the research published 
to date. Namely, the identification ofnon-sequence-specific effects 
ofa 4 guanosine r peat present in all published c-myc and c-myb AS 
sequences.18 The role of the 4G tetramer isunclear; the sequence 
may form DNA-protein complexes, form an unusual conforma- 
tion, or form triplex or tetraplexes with the DNA itself, inhibiting 
DNA synthesis n general. 18,19 Further uncertainty is generated by 
the susceptibility of these compounds to nuclease digestion, 
primarily in the 3' to 5' direction, in the extracytoplasmic and 
intracytoplasmic space. This problem is diminished when phospho- 
rothiated OGD are used. 2° However, modification adds further 
variables to the question of sequence specificity. 
Oligonucleotides are large, negatively charged structures that 
cannot passively cross the cell membrane. Two mechanisms for 
internalization have been identified. One method involves adsorp- 
tive endocytosis via binding to an 80kD cell surface protein 
accounting for a small percentage of total OGD uptake. 2° The 
majority of O GD uptake is performed by fluid phase pinocytosis.20 
The sequence of events from cellular uptake to nuclear localization 
is not well defined. Delivery of these AS OGD to the nucleus can be 
enhanced by liposome packaging, viral vectors, direct microinjec- 
tion, and electroporation. 21 
Despite the questions about sequence specificity, mechanism 
ofacrion, and mode of cellular delivery, these substances have been 
quite effective in reducing smooth muscle cell proliferation i vitro 
and neointimal hyperplasia n vivo. ts-17 Optimal delivery of these 
compounds to the desired site of action remains elusive. Preferably, 
the OGD could be delivered via remote access at the time of 
intervention ifpercutaneous techniques are used or applied irectly 
to the anastomotic site if a traditional bypass is being performed. 
Much work has been performed using an elegant technique of a 
double balloon catheter with delivery ports between the two 
balloons. With this technique the thymidine ldnase gene via an 
adenoviral vector has been delivered to balloon-injured pig il- 
iofemoral arteries. The tk gene makes the SMCs sensitive to 
ganciclovir, thereby offering a mechanism to inhibit their prolif- 
eration. 22 Another effective balloon-directed technique involves 
the use of a porous balloon to delivery the OGD under higher 
pressures This technique is applicable to the peripheral vascula- 
ture, but may cause prolonged ischemia in the coronary system. 
Electroporation is an efficient method of transiently opening 
cell-membrane channels that has been useful in the in vitro setfng 
to introduce genetic material into the cell. Until recently ithas not 
been useful in the in vivo setting. Our lab has recently developed an 
in vivo technique using a modified form ofelectroporation that has 
high viability compared with standard electroporation. Preliminary 
results are promising with the introduction of high molecular 
weight compounds into SMC of human umbilical cord explants. 
Other techniques involve liposome formation as a means of 
increasing the efficiency of cellular uptake. Liposome constructs 
include Hemagglutinating virus of Japan (HIV)-fipid, the cationic 
lipids N-[1-(2,3 dioleyloxy)propyl]-N,N,N-triethylammonium 
chloride (DOTMA) and N-[l(2,3-dioleyloxy)propyl]-N,N,N tri- 
methyl ammonium ethylsulfate (DOTAP) (Nakayama DK, per- 
sonal communication. 23,24 Liposome-enhanced delivery has been 
used effectively in vivo with direct infusion into the balloon-injured 
vessel with proximal and distal control of the vessel. 2s Another 
technique to provide longer-term exposure of the vessel to the AS 
sequence is to dissolve the OGD in a plurionic gel or fibrin glue. We 
have effectively inhibited porcine VSMC growth with c-myc AS in 
a fibrin glue system in vitro. 26 This may prove to be an effective 
technique for delivery to exposed vessels during distal bypass 
procedures. No matter what echnique of delivery is used it must be 
(1) safe, (2) user-friendly, and (3) inexpensive. 
Antisense technology provides a more specific and hopefully 
more effective method of controlling the neointimal response to 
vessel wall injury. Carefully controlled studies to elucidate the 
sequence-specific versus nonspecific effect of AS OGD are re- 
quired. The long-term effects of inhibiting the "healing" response 
after vascular anastomosis or angioplasty have yet to be determined. 
What is the optimal delivery vehicle? Can long-term inhibition of 
SMC proliferation be maintained in vivo? What are the optimal 
genetic targets? c-myc is attractive because of its early requirement 
for cellular DNA synthesis, but this target may b e central for the 
maintenance of normal cellular function. Will vessels thin and 
become aneurysmal with long-term inhibition of SMC DNA 
synthesis? All of these questions and many more remain to be 
answered before antisense therapy can be offered to our patients. 
Blair A. Keagy, MD 
Geoffrey L. Risley, MD 
University of North Carolina 
Chapel Hill, N.C. 
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GENET ICALLY  ENHANCED 
CARDIOVASCULAR IMPLANTS 
LOCAL RELEASE OF  B IOACTIVE  SUBSTANCES 
FROM METALL IC  STENTS 
Coronary artery stenting with permanent metallic implants is 
arguably the most important advance in interventional cardiology 
since balloon angioplasty. More than 250,000 devices were im- 
planted in the United States during 1995, and the growth of 
stenting is expected to be exponential for the next several years. 
Stenting, however, is associated with three important problems: 
thrombosis, restenosis, and inapplicability to smaller coronary 
vessels. These problems limit extension of stenting to a much 
broader cohort of patients, and problems form the rationale for 
developing new stent echnologies. 
The first problem is that stent hrombosis occurs during the 
first 3 weeks after implantation i  1% to 10% of patients, depending 
on a host of factors that predict hrombotic risk. Stent hrombosis 
is a sudden catastrophic event hat most often presents as acute 
myocardial infarction with a high incidence of death. Newer 
antiplatelet agents and optimal stent deployment techniques are 
making asignificant impact on stent hrombosis; however, the most 
popular antiplatelet therapy with ticlopidine has a 2% incidence of 
agrannlocytosis, and overly aggressive deployment can result in 
acute complications requiring additional stenting or emergency 
bypass urgery. 
Stent hrombosis appears to be mediated by multiple mecha- 
nisms. We have demonstrated in aporcine x-vivo shunt model that 
shear stress caused by high flow velocity in small vessels, inad- 
equately expanded stents, and microshear f om rough stent sur- 
faces activates platelets and promotes platelet-rich t rombosis. The 
extent of vessel injury by the deployed stent also contributes to 
thrombosis. We have shown in rabbit carotid and pig coronary 
models with two stent types that the extent of vessel injury 
measured by the depth of strut penetration a d the extent ofmediai 
smooth muscle cell necrosis directly correlates with the mass of 
fibrin-rich thrombus adherent to stents in the first 4 to 7 days after 
implantation. Systemic and local prothrombotic and fibtinolytic 
factors probably also play an important role. 
The second problem isthat current restenosis rates remain too 
high for more widespread pplication. Coronary stenting isthe only 
device or therapy thus far to reduce the incidence of restenosis. 
Although restenosis rates are significantly lower than those for 
conventional balloon angioplasty in ideal, de novo lesions, resteno- 
sis still occurs in 15% to 20%. Ideal lesions only account for about 
one fourth of current stent cases. The majority of stents are placed 
in more complex lesions, including restenotic lesions, saphenous 
vein grafts, ostial esions, long lesions, and chronic total occlusions. 
In these more complex anatomies, stent restenosis occurs in 35% to 
50% of cases. 
The mechanism ofrestenosis differs in stenting comparcd with 
balloon or atherectomy angioplasty. In the latter cases, unfavorable 
vessel remodeling (vessel shrinkage) predominates in three fourths 
of cases. Neointimal proliferation occurs frequently but accounts 
for only a minor portion of the late loss of luminal dimensions. With 
stenting, the scaffolding support of the implant eliminates recoil 
and unfavorable vessel remodeling after injury. The only mecha- 
nism ofrestenosis with stents is exaggerated neointima formation 
resulting from vascular injury-induced smooth muscle cell migra- 
tion and proliferation. Thus stenting isthe ideal injury to study the 
effects of antiproliferative strategies. 
Lastly, stent placement has been largely confined to vessels with 
a normal reference diameter >2.7 mm. This is because thrombosis 
and restenosis rates are even higher for smaller vessels. This is 
important because approximately 50% of all angioplasties are 
performed in these smaller vessels. 
We believe that a metallic stent hat is capable of delivering a 
variety of substances in high concentration precisely to the site of 
arterial injury may be advantageous fordiscovering and implement- 
ing successful treatment s rategies for thrombosis and restenosis. 
Our fundamental im is to create ahybrid device consisting of an 
optionally removable hitinol coronary stent combined with a 
polymer membrane local pharmacologic delivery system that will 
address the relevant clinical problems of stenting. 
We have developed a practical method of covalently linking 
a molecular monolayer of PEO or pleuronics to a metal or 
polymer membrane surface. This surface modification (200 ng 
PEO/stent) reduces high shear stress (2100s-1)-induced platelet 
adhesion and thrombus accumulation on the stent by 95% versus 
controls in a porcine ex-vivo shunt mode. This modification is
significantly (fivefold to 10-fold) more effective than systemic 
aspirin (10 mg/kg), or heparin (100 U/kg), and is equivalent to 
systemic treatment with the monoclonal ntibody to Gp IIbIIIa 
m7E3 at 8 gg/kg. Six-month canine coronary implants how no 
thrombosis or local inflammatory changes. Nitinol stent sur- 
face modification with PEO appears to be biocompatible and 
appears to effectively prevent stent thrombosis n these animal 
models. 
We have previously shown that stents coated with a polyure- 
thane membrane are capable of loading milligram quantities of 
small lipophilic drugs and delivering them to the arterial wall in 
locally high and sustained concentrations. Weare currently devel- 
oping a modification of this polymer that contains a controllable 
network of hollow cells and interconnecting channels which vary 
from 2 to 10 gm in diameter. This porous membrane is designed to 
permit uptake of significant quantities of hydrophilic molecules, 
including proteins, oligonucleotides, and viral vectors for gene 
therapy. So far, these porous membranes can concentrate model 
large molecules uch as lysozyme at concentrations more than 
100-fold greater than the control, nonporous membranes. The 
polymer-coated stent will be tested for biocompatibility and 
mechanical properties in the rabbit carotid and pig coronary 
models. 
We are currently exploring local drug delivery with three 
candidate substance classes, all of which may affect he genetic 
programming of the local vascular microenvironment at the level of 
the vascular smooth muscle cell. The first candidate agent is 
octreotide, a hydrophilic polypeptide somatostatin a alog. We have 
demonstrated that octreotide inhibits vascular smooth muscle cell 
